<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47915">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02482428</url>
  </required_header>
  <id_info>
    <org_study_id>CLFX453X2202</org_study_id>
    <nct_id>NCT02482428</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Topical LFX453 for External Genital Warts</brief_title>
  <official_title>A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LFX453X2202 study will test the investigational drug LFX453 against placebo for safety,
      tolerability, and efficacy in treating genital warts in circumcised men, in parallel with an
      additional open label arm using imiquimod 5%.

      During the study the patients will receive either LFX453, placebo or active comparator and
      the tolerability and safety will be assessed continuously through local tolerability
      assessments and adverse event recording. Efficacy will be clinical evaluations and lesion
      count. During the study biopsies will be taken for analysis of pharmacokinetics and
      biomarkers. Blood samples will be taken for safety, pharmacokinetics (PK), and biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clearance of disease</measure>
    <time_frame>14 weeks</time_frame>
    <description>Proportion of patients achieving complete clearance of genital warts within 14 weeks of treatment start</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events of LFX453</measure>
    <time_frame>30 weeks</time_frame>
    <description>Assessment of safety and tolerability as measured by adverse events and local tolerability scores</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>External Genital Warts</condition>
  <arm_group>
    <arm_group_label>LFX453 CSF1 Twice Daily applications</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LFX453 CSF2 Twice Daily applications</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LFX453 Vehicle CSF1 Twice Daily applications</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 weeks treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LFX453 Vehicle CSF2 Twice Daily applications</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 weeks treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aldara® 3 applications per week</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16 weeks treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFX453</intervention_name>
    <description>The cream will be applied twice daily for up to 12 weeks</description>
    <arm_group_label>LFX453 CSF1 Twice Daily applications</arm_group_label>
    <arm_group_label>LFX453 CSF2 Twice Daily applications</arm_group_label>
    <arm_group_label>LFX453 Vehicle CSF1 Twice Daily applications</arm_group_label>
    <arm_group_label>LFX453 Vehicle CSF2 Twice Daily applications</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldara®</intervention_name>
    <description>Cream will be applied 3 times a week for 16 weeks</description>
    <arm_group_label>Aldara® 3 applications per week</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Circumcised male 18-60 years

          -  Clinical diagnosis of external genital warts

          -  Agree to remain abstinent or to use condoms during intercourse for the duration of
             the study

          -  Agree to digital photographs of treated area

        Exclusion Criteria:

          -  Any treatment of genital warts within one month of treatment start

          -  HPV vaccination

          -  presence of warts larger than 200 mm2

          -  Genital herpes within one month of treatment start

          -  History of Bowenoid papulosis

          -  significant illness within 2 weeks of treatment start

          -  use of other investigational drugs

          -  known hypersensitivity to study drugs or constituents

          -  history of ECG abnormalities

          -  History of significant heart conditions

          -  Impaired renal function

          -  Abnormal liver function

          -  History of immunodeficiency disease

          -  Drug or alcohol abuse

          -  Immunosuppressive therapies

          -  Malignancies in the past 5 years

          -  hypertrophic scarring
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 5, 2016</lastchanged_date>
  <firstreceived_date>May 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human papilloma virus (HPV), Genital Warts, Sexually transmitted disease (STD), viral disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
